CLASSIFICATION OF LABOR ABNORMALITIES (DYSTOCIA): CAUSES, CLINICAL FEATURES, MANAGEMENT TACTICS FOR VARIOUS TYPES, AND PHARMACODYNAMICS/PHARMACOKINETICS OF AGENTS USED IN LABOR MANAGEMENT

Labor abnormalities, commonly referred to as dystocia, encompass a spectrum of disorders disrupting the normal progression of labor, leading to prolonged or arrested labor, maternal exhaustion, fetal distress, and increased risks of operative interventions such as cesarean sections. This review systematically classifies dystocia into categories based on power (uterine contractions), passenger (fetal factors), passage (pelvic anatomy), and psyche (maternal psychological factors), delineating their etiological causes including cephalopelvic disproportion, malposition, inadequate contractions, and maternal comorbidities like obesity or diabetes. Clinical manifestations range from stalled cervical dilation (<1 cm/hour in active phase) to abnormal fetal heart rate patterns, necessitating vigilant monitoring via partograms and cardiotocography. Management tactics vary by type: for hypotonic dysfunction, augmentation with oxytocin; for cephalopelvic disproportion, timely cesarean; and for malposition, positional changes or instrumental delivery. Pharmacological agents play a pivotal role, with oxytocin's pharmacodynamics involving uterine G-protein coupled receptor activation to enhance contractions (half-life 3-5 minutes, rapid IV onset), prostaglandins like misoprostol promoting cervical ripening via prostaglandin E1 receptor agonism (bioavailability 80-90% oral), and tocolytics such as nifedipine inhibiting calcium channels to relax myometrium (peak plasma 30 minutes). Drawing from meta-analyses and guidelines (2010-2025), dystocia affects 10-20% of labors, with cesarean rates rising to 30-40% in affected cases, particularly in nulliparas. The topic's relevance is heightened by global maternal morbidity (e.g., postpartum hemorrhage in 10-15%) and neonatal risks (asphyxia in 5-10%), underscoring the need for evidence-based protocols to optimize outcomes. High potential exists in AI-assisted monitoring and personalized pharmacokinetics via genetic profiling (e.g., CYP3A4 variants affecting drug metabolism). This article provides a structured synthesis, incorporating diagnostic algorithms, therapeutic decision trees, and pharmacokinetic models to guide obstetricians in resource-diverse settings.

Hali tarjima qilinmagan